The ExoView™ platform provides the ability to measure up to 4 markers on a single extracellular vesicle, with single binding event sensitivities. Measure even the smallest EVs with confidence.


Complete Characterization of Extracellular Vesicles



3 color fluorescence. Single binding event sensitivities mean that even the smallest EVs are detectable

Icon_Biomarker_colocalization_light_brackground FOR WEB.png


Measure up to 4 proteins per EV. Measure EV sub-populations through relative protein expression

Icon_EV_Cargo_light_background FOR WEB.png


Probe for luminal EV proteins and cargo in single EVs

Icon_EV_Count_light_background FOR WEB.png


Count the number of antigen positive EVs direct from sample with no purification.

Icon_EV_size_light_background FOR WEB.png


Measure with high resolution, the size of individual antigen positive EVs

Icon_No_purification_requireD_light_background FOR WEB.png


Measure the changes in your sample, not the biases from your purification technique. 



Capture can characterize multiple populations of EVs from a single sample using many surface markers

Icon_Streamlined_Workflow_light_background FOR WEB.png


Automated instrument measurement and paralleled sample preparation reduce hands-on time and sample throughput 



Range of validated capture antibodies available. Custom design (direct or via secondary antibodies) also available 




Measure 3 color fluorescence on single EVs which are bound to the ExoView™ microarray chip.

Extracellular vesicles are captured from solution without purification and bound to one of 6 different capture antibodies (plus control) on the surface of the ExoView™ chip.

Secondary fluorescent antibodies can be added, and up to 3 colors can be measured simultaneously. The secondary antibodies are common to all 6 capture antibodies.

Single binding event sensitivities mean that even poorly expressed proteins on the smallest of extracellular vesicles are detectable through the high sensitivity of ExoView™.




Biomarker colocalization (4 markers per EV) allows unique sub-populations of extracellular vesicles to be identified and measured.

This image shows vesicles bound to a single anti-CD41a spot on the ExoView™ chip. All vesicles imaged on this spot are therefore positive for CD41a.

Once bound, the vesicles have been stained with a 3 color fluorescent cocktail of antibodies against CD63/CD81/CD9. 

Blue Spots are vesicles that are positive for CD41a + CD63. 
Green Spots are vesicles that positive for CD41a + CD81. 
Red Spots are vesicles that are positive for CD41a + CD9. 
Other colors are vesicles that express various combinations of R/G/B fluorescent signal and CD41a (via capture on surface). 

All vesicles are simultaneously sized and counted.




Once bound to the ExoView™ chip, extracellular vesicles can be permeated and probed for luminal proteins and cargo. 3 color fluorescence allows a combination of staining of 3 surface and/or luminal proteins on single extracellular vesicles.

These experiments show the ability to detect luminal proteins such as ALIX and Sytenin through the permeabilization of bound extracellular vesicles.

Icon_No_purification_requireD_light_background FOR WEB.png



Variability and biases introduced through sample purification are commonly cited as the largest limiting factor in the progression of EV-based platforms into clinical diagnostics and therapeutics.

It is commonly accepted that the methods used in sample collection and isolation can significantly influence the downstream analysis of vesicles with regards to their function, content, physical form, and count.  Soluble proteins, protein aggregates, lipoproteins, cell organelles, and viruses are candidates for co-purification. Common nanoparticle characterization techniques, such as NTA and TRPS, are unable to discriminate particles that co-purify and are subject to errors in data interpretation.  These co-purified particles influence EV counts that are measured and limit the ability to link clinical observations to measured data. 

See Example

For example, when purifying blood plasma by ultracentrifugation, the majority of detectable particles measured within a sample were found to be lipoproteins rather than EVs in a publication by Sódar et al. 2016. These contaminants make it difficult to relate experimental or clinical changes to measured data. Rare events present in biological samples make the presence of contaminants even more challenging. Non-specific techniques are confounded by contaminants as well as by EVs that are not of interest

ExoView bypasses these challenges by measuring only specific EVs that exhibit target surface antigens. It does so without the need for sample purification. The platform works with as little as 35µL of sample and provides EV phenotype, size and count direct from biological fluids onto a functionalized array without the need for purification. EVs have been measured directly from the following samples without the need for ANY purification:

  • Cell culture with or without bovine EVs (no cross reactivity to human antibodies on capture array)

  • Blood plasma

  • Blood serum

  • Cerebrospinal fluid (CSF)

  • Saliva

  • Follicular fluid

  • Synovial fluid

See ExoView in eal-time

This video shows vesicles binding to the ExoView array in real time. The EVs bind to the surface via an antibody/antigen interaction and therefore requires no labeling and no purification of the EV sample. Once bound, the size and count of antigen positive EVs are measured.

Common issues with purification




Icon_Streamlined_Workflow_light_background FOR WEB.png


ExoView has been designed specifically to address the needs of EV researchers. The microarray format allows for many probes to be measured simultaneously, dramatically increasing throughput. The ExoView Tetraspanin Kit contains arrays that have been functionalized with antibodies against CD9, CD63, CD81, CD41a plus IgG negative control. Additionally, customers can work with NanoView Biosciences to design arrays with antibodies against an antigen of their choice.


Icon_EV_size_light_background FOR WEB.png


ExoView™ uses Single Particle Interferometric Reflectance Imaging Sensing (SP-IRIS) to measure the size of single EVs with high precision by analyzing the enhanced interferometric signal of bound EVs when attached to a layered substrate. Using this methodology, EVs as small as 50nm can be imaged and measured. The enhanced interferometric signal has a radius^3 relationship between size and signal intensity that provides excellent resolving capabilities when compared to existing techniques such as nanoparticle tracking analysis (NTA). EV preparations often exhibit a broad range of sizes and sub-populations, therefore sizing resolution can impact how well a technology can accurately characterize EV samples. ExoView has significantly stronger peak-to-peak resolution and can more accurately resolve distinct vesicle sub-populations within a heterogeneous sample. When using NTA, EVs with a size difference of 2X will result in a 2X difference in scattering, whereas ExoView achieves an 8X difference. Furthermore, unlike NTA, the presence of larger EVs does not obscure or bias the relative count of particles within a heterogeneous sample population.

Unrivaled peak-to-peak size resolution - more info

ExoView has unrivaled peak-to-peak size resolution as demonstrated by its ability to resolve five particle populations of differently sized NIST certified polystyrene beads (40nm, 70nm, 100nm, 150nm, and 200nm) within a single measurement. While polystyrene beads are not a good analog for EVs, the experiment serves to demonstrate the inherent resolving capabilities of the technique.

NIST particles (50nm, 100nm, 150nm, and 200nm) and their specified distrubtions. The solid blue line is the ExoView results for a 4 particle mixed sample.


Icon_EV_Count_light_background FOR WEB.png



The number of EVs bound to a chip can be measured and related to a concentration of antigen-positive EVs in solution. Control tests are performed to ensure that the binding events measured are specific and not related to non-specific binding or aggregates associated with the antibody used to functionalize the chip surface. The array is measured prior to sample incubation and any contaminant events can be excluded from the analysis. Similarly, non-specific binding events observed on the negative control can be subtracted from experimental results.

The graph to the left shows the linearity response of the ExoView instrument. As a measure of comparability, a sample of EVs was measured using an NTA instrument. The sample has been linearly diluted and measured using the ExoView platform and the number of CD81-positive EVs were counted at a range of dilutions.


Measure up to 4 markers on a single extracellular vesicles